Xiuning le, MD
Internal Medicine · Boston, MANPI 1720399074
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $256,036 of the $363,775 with a category attached, or 70.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 15.6%. 2025 is the largest year on record at $96,303, more than ten times the $9,361 reported in 2019. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $1018.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- EMD Serono, Inc.$35K
- Regeneron$25K
- Bayer$24K
- Astrazeneca UK Limited$22K
- Merck Kgaa$20K
- plus $181K from 25 others
Across 869 payments — averaging $8659.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$1.9M
- AstraZeneca$1.7M
- Regeneron$1.1M
- Eli Lilly$481K
- EMD Serono Research & Development Institute, Inc.$478K
- AbbVie$345K
- plus $1.5M from 12 others
What the payments were for
- Consulting fees$256,03670%
- Speaking & faculty fees$37,05110%
- Grants$18,1825%
- Travel & lodging$39,33711%
- Food & beverage$8,4262%
- Education$4,7431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $56,686 |
| EMD Serono, Inc. | 52 | $35,112 |
| Regeneron | 39 | $24,868 |
| Bayer | 16 | $23,851 |
| Astrazeneca UK Limited | 30 | $21,903 |
| Merck Kgaa | 7 | $20,158 |
| Genentech, Inc. | 1 | $18,182 |
| Johnson & Johnson | 16 | $15,435 |
| Daiichi Sankyo Inc. | 22 | $15,326 |
| Blueprint Medicines Corporation | 22 | $14,239 |
| AbbVie | 12 | $13,541 |
| Janssen Scientific Affairs, LLC | 12 | $13,455 |
| Boehringer Ingelheim International GmbH | 8 | $12,065 |
| Merck | 10 | $9,577 |
| Biontech SE | 8 | $9,022 |
| Eli Lilly | 3 | $8,405 |
| Janssen Research & Development, LLC | 5 | $8,162 |
| E.r. Squibb & Sons, L.L.C. | 13 | $8,143 |
| Boehringer Ingelheim | 5 | $6,982 |
| Pfizer | 6 | $5,760 |
| Janssen Global Services, LLC | 7 | $4,416 |
| Lilly USA, LLC | 4 | $4,309 |
| Novartis | 2 | $3,900 |
| Taiho Oncology, Inc. | 2 | $2,736 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,500 |
| Novartis Pharma AG | 1 | $2,363 |
| Regeneron Healthcare Solutions, Inc. | 7 | $2,045 |
| Genentech USA, Inc. | 3 | $257 |
| Jazz Pharmaceuticals Inc. | 2 | $178 |
| Mirati Therapeutics, Inc. | 1 | $122 |
| Spectrum Pharmaceuticals Inc. | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$363,775 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 59 | $1,044,528 |
| MekinistTrametinib Dimethyl Sulfoxide | 15 | $302,188 |
| TafinlarDabrafenib Mesylate | 16 | $235,168 |
| LumakrasSotorasib | 11 | $207,655 |
| RozlytrekEntrectinib | 13 | $177,176 |
| Dexamethasone | 29 | $341 |
| Ondansetron Hcl | 36 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $56,686 | $1,044,52859 claims |
| NovartisMekinist, Tafinlar | $3,900 | $537,35531 claims |
| Genentech USA, Inc.Rozlytrek | $257 | $177,17613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
- Ryan CorcoranBoston$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.